Shoulson I.

Methods	30‐week double‐blind, in parallel study (12 weeks follow‐up). Method of randomisation: stratification by age and stage of ilness. Results presented for each arm of the trial. Per‐protocol data analysis. Location: 1 centre (USA).
Participants	60 patients, 11 drop‐outs. 24 male patients and 25 female patients. Mean age of participants: 39,4±10.4 years. Mean duration of disease: 5,3± 3.3 years. Inclusion criteria: HD (unexplained movement disorder and positive family history), >18 years of age, early stage disease (functional stages I‐II), satisfactory general medical health, person for support and company. Exclusion criteria: serious psychiatric illness (major depression with antidepressant medication, psychotic illness requiring antipsychotics, active suicidal behavior).
Interventions	Ora Baclofen 60 mg/day (30 patients) and placebo (30 patients). No titration.
Outcomes	Change in mTFC‐UHDRS.
Notes	Negative for efficacy measures.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear